BioCentury
ARTICLE | Company News

FDA approves Array's drug combo to treat melanoma

June 27, 2018 10:04 PM UTC

Array BioPharma Inc. (NASDAQ:ARRY) said FDA approved Braftovi encorafenib in combination with Mektovi binimetinib to treat BRAF V600 mutation-positive unresectable or metastatic melanoma. The company said the combo is now available, but declined to provide a wholesale acquisition cost (WAC).

In February, Array reported that the combo significantly improved median overall survival compared to BRAF inhibitor Zelboraf vemurafenib in the Phase III COLUMBUS trial (see "Array Gains on Phase III OS Data in Melanoma")...